Pentoxifylline
Brand names: Pentoxifylline
At a glance
- Medicare prescriptions, 2024
- 220,131
- Medicare drug cost
- $7.1M
- Average cost per prescription
- $32.14
- Clinicians who prescribed it
- 7,276
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline extended-release tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease.
From the FDA-approved prescribing information (label dated May 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- General Practice 24.3%
- Internal Medicine 17.6%
- Family Medicine 16.3%
- Nurse Practitioners 10.6%
- Dermatology 3.3%
- Physician Assistants 3.1%
- Vascular Surgery 2.6%
- Nephrology (Kidney) 2.3%
- Cardiology 2.2%
- Podiatrists 1.8%
- Radiation Oncology 1.6%
- Urology 1.6%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 12% from 2019 to 2024.
Biggest change by state since 2019
- Louisiana +9%
- North Carolina +3%
- Pennsylvania −2%
- Ohio −7%
- Kentucky −9%
- California (smallest change) −27%
- Tennessee (smallest change) −22%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Advagen Pharma Ltd.,
| Strength | Looks like | Imprint |
|---|---|---|
| 400 mg | pink oval tablet, 17 mm | TRENTAL V |
Apotex Corp.
| Strength | Looks like | Imprint |
|---|---|---|
| 400 mg | white oval tablet, 16 mm | APO 033 |
Ax Pharmaceutical Corp
| Strength | Looks like | Imprint |
|---|---|---|
| 1 g | white powder | |
Rising Pharma Holdings, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 400 mg | purple oval tablet, 16 mm | R856 |
Validus Pharmaceuticals LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 400 mg | pink oval tablet, 17 mm | TRENTAL V |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.